Pope Francis (Credit: X)
Pope Francis injured his right arm after suffering a fall earlier this week. According to the Vatican, while the 88-year-old pontiff did not break his arm, a sling was put on as a precaution. This incident comes just weeks after another fall on December 7, where he hit his chin on a nightstand, resulting in another, visible bruise. The pope's health has been a topic of ongoing speculation due to his age and medical history, which includes long bouts of bronchitis and mobility challenges. Often seen using a wheelchair or a cane, Francis also uses a walker within the Vatican's Santa Marta hotel, where he resides. Notably, his frailty has brought renewed attention to the risks of falls among elderly individuals and the steps one must follow to mitigate such falls.
A study published in Frontiers in Aging Neurosciences people get older, the bone density in the lower back and thigh bone decreases significantly. This raises the risk of osteoporosis (OP). Therefore it becomes pivotal to pay early attention to nutrition, exercise ability, vitamin D levels, and uric acid levels in older individuals to prevent Ostreopsis and mitigate fall risks. The risk of falls and bone injuries among elderly individuals underscores the importance of preventive measures for maintaining bone health and minimizing fall risks.
Elderly, particularly menopausal women, require a daily calcium intake of 1,200 mg, divided into two or more doses. This can be achieved through dietary sources such as dairy and non-dairy products or through supplements like calcium carbonate and calcium citrate. However, total daily calcium intake should not exceed 2,500 mg to avoid potential health risks.
Vitamin D is essential for calcium absorption and bone mineralization. While sunlight exposure helps synthesize vitamin D, older individuals often require supplements due to reduced skin synthesis and the limited availability of foods. Fortified milk and supplements containing 200–600 IU of vitamin D daily are recommended, with higher doses required for those with deficiencies. Severe cases may necessitate high-dose treatments, such as 50,000 IU weekly for up to three months, along with regular monitoring of calcium and vitamin D levels.
Regular exercise is vital for preserving bone mass and reducing fall risk. Weight-bearing activities, strength training, and balance exercises like brisk walking or skipping can enhance bone density and improve coordination. Experts recommend at least 30 minutes of moderate physical activity most days of the week, supplemented by strength training twice weekly. For individuals unable to engage in standard exercise routines, alternatives like vibrating platforms may help maintain bone health.
Falls remain a leading cause of fractures among individuals over 60. Addressing contributing factors such as balance issues, vision problems, and environmental hazards can significantly reduce risks. Preventive measures include regular vision checks, minimizing medications causing dizziness, improving home safety (e.g., installing railings and removing loose rugs), and wearing rubber-soled footwear. Hip protectors may also help mitigate the impact of falls.
Credit: iStock
American drugmaker Eli Lilly has sued six companies in the US over the alleged illegal sale of its experimental weight-loss drug retatrutide.
In a statement, Lilly said that the lawsuits target US entities allegedly selling illegal retatrutide products, claiming that their products are for “research use only” while allegedly marketing them for human use. These include
“Retatrutide is being rigorously studied as part of a comprehensive clinical trial development program,” said David A. Hyman, Lilly’s chief medical officer.
“We take the responsibility of evaluating the safety and efficacy of our investigational medicines seriously. What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk,” he added.
Lilly has filed lawsuits against:
Lilly said it has referred more than 200 individuals and entities to the US Food and Drug Administration (FDA), the US Department of Justice, state attorneys general, law enforcement agencies and professional licensing boards.
The company is also working with regulators, law enforcement and customs authorities worldwide to address the illegal market.
Lilly urged social media and e-commerce platforms, credit card companies, payment processors, and shipping and logistics companies used by sellers to help protect patients and tackle the illicit activity.
The drugmaker noted that it has reported more than 14,000 websites, advertisements, social media posts and product listings that allegedly market retatrutide unlawfully across more than 100 countries to internet service providers, social media platforms and e-commerce companies.
The US FDA has made clear that selling unapproved retatrutide directly to consumers is illegal. Retatrutide also cannot be lawfully compounded.
The FDA has warned that so-called “research-use only” products are of unknown quality and may pose risks to consumers’ health.
Black-market sellers and businesses posing as legitimate medical providers have openly marketed retatrutide as a weight-loss “hack.”
According to Lilly, such products are frequently made by unregulated foreign manufacturers. Regulators, customs agencies and law enforcement authorities worldwide have warned about these products and have taken actions including raiding clandestine manufacturing sites, seizing shipments and making arrests.
Retatrutide is one of Eli Lilly’s next-generation obesity treatments and is currently under development. Unlike Lilly’s currently approved GLP-1 drugs, retatrutide activates three hormone receptors: GLP-1, GIP and glucagon.
Researchers believe this triple-action approach could help people lose excess weight by reducing appetite while also increasing energy expenditure.
Retatrutide has attracted significant interest after late-stage clinical trials showed some of the highest weight-loss outcomes reported with an obesity medication. In Phase 3 studies, adults without diabetes who received the highest dose lost more than 28% of their body weight over 80 weeks.
Lilly plans to submit retatrutide for approval to the US FDA in the first quarter of 2027.
Credit: AP Photos
President Donald Trump on Monday signed an executive order calling for fewer routine childhood vaccinations and directing the Justice Department to challenge state vaccine laws, a move swiftly rejected by physicians and vaccine makers.
The order, signed on August 10, calls for childhood vaccines to be administered at separate medical visits whenever possible and narrows federal recommendations to vaccines against 11 core diseases.
"For too long, America recommended more childhood vaccines than any peer nation. No longer," the White House share in a post on X.
It also directs federal health agencies to develop a plan for separate measles, mumps and rubella vaccines, which are currently not available as individual shots in the US.
The executive order, titled “Delivering Gold Standard Childhood Vaccine Recommendations for Americans,” cuts the number of vaccines recommended for all children from 18 to 11.

Also read: Donald Trump Signs Order To Split MMR Vaccine: Is It Safe For Children?
The order calls for the combined MMR vaccine to be replaced by separate measles, mumps, and rubella shots.
The MMR vaccine currently protects children against all three diseases with a combination shot. Under existing CDC guidance, children receive two doses, generally at 12 to 15 months and again at 4 to 6 years.
Trump claimed that “there could be a possibility” the MMR vaccine is “quite lethal,” but said that when separated, the vaccines are “not at all lethal, but just very effective.”
Trump also suggested that vaccines cause autism, despite a lack of scientific evidence showing a link.
The CDC and many major medical groups have long recommended the combined vaccine because it reduces the number of injections and lowers the risk that children will miss protection against one of the three diseases.
The new executive order does not immediately replace the current CDC childhood immunization schedule. It, instead, directs the HHS Task Force on Safer Childhood Vaccines to develop plans within 90 days to assess vaccine timing and sequencing and adjust the federal schedule as appropriate and consistent with applicable law.
There are also logistical hurdles. Individual measles, mumps and rubella vaccines are not currently licensed in the US. The combined MMR vaccine is manufactured by Merck and GSK for the US market. Merck stopped making single-disease shots for measles, mumps and rubella in 2008, and such vaccines are not routinely used in most other countries.
Merck and GSK said there is no published scientific evidence supporting separation of the vaccines and that decades of evidence support the safety of the combined MMR vaccine.
“Even under current expedited review pathways, it could take years — potentially as many as 10 — to meet the safety and efficacy requirements to obtain FDA approval and then begin manufacturing and commercialization” of single-disease shots, Merck said.
Dr. Andrew Racine, president of the American Academy of Pediatrics, said that although it is possible to separate the MMR vaccine into its individual components, each component would need to be manufactured and tested.
“They wouldn't be able to do that probably for another 10 years, and there's no indication that they have any interest in doing that,” Racine was quoted by Reuters as saying.
Read More: Amid Cyclospora, Salmonella Outbreaks, US FDA Issues Guidance on Ready-to-Eat Produce
Taking to social media platform X, WHO Director-General Dr. Tedros Adhanom Ghebreyesus said that “vaccines are among the most powerful tools” for keeping children safe and “making deadly diseases preventable.”
Expressing concern about the changes to US immunization policy, the WHO said they “are not aligned with decades of evidence that show when children are most vulnerable to disease, when vaccines provide the strongest protection, how many doses are needed, and which vaccines can be given together safely.”
“The current evidence is unequivocal: vaccines — including the MMR vaccine — are safe and do not cause autism,” he said, adding that “delaying vaccines or separating doses unnecessarily does not make vaccination safer and can leave children unprotected.”
Dr. Andrew Racine, president of the American Academy of Pediatrics, said the announcement could create unnecessary uncertainty for families.
“Science about vaccines and their efficacy has not changed,” Racine said.
Credit: iStock
People working night shifts were nearly twice as likely to develop long COVID, according to a new study.
Researchers at Spain’s ISGlobal said no previous study had examined whether disruption of the body’s biological clock could increase the risk of developing long COVID.
“Our findings suggest that circadian disruption plays a role in the transition from acute infection to persistent symptoms,” said Manolis Kogevinas, an ISGlobal researcher.
Published in the Scandinavian Journal of Work, Environment and Health, the study also found that chronic insomnia further increased the risk, highlighting the potential importance of healthy sleep habits in preventing long COVID and other post-acute infectious syndromes.
Also read: Long COVID Patients May Face Brain Fog & Fatigue Due To Reduction In Dopamine? New Study Explains
The research team followed 2,941 adults in Catalonia between 2021 and 2023. Among the 1,899 participants who became infected with SARS-CoV-2, 284 developed long COVID during the two-year follow-up.
Long COVID was defined as persistent symptoms lasting more than three months after infection.
Compared with day workers, people who worked night shifts had an 88% higher risk of developing long COVID. This was after accounting for other factors, including vaccination history and chronic diseases.
The association was stronger among night workers with obesity.
Importantly, the increased risk was seen in both current and former night workers, suggesting that it may reflect longer-term effects of circadian disruption rather than short-term changes.
However, night-shift work was not associated with a higher risk of infection. This suggests that disruption of the biological clock may influence how the body recovers from infection rather than the likelihood of catching the virus.
Read More: Amid Cyclospora, Salmonella Outbreaks, US FDA Issues Guidance on Ready-to-Eat Produce
The researchers found that chronic insomnia independently increased the risk of long COVID by 42%, regardless of night shift work.
The two factors also appeared to have a synergistic effect. Night shift workers with chronic insomnia were 2.7 times more likely to develop long COVID than day workers without insomnia.
The biological mechanisms behind the association are not yet fully understood. Researchers noted that the time of day when the body encounters a pathogen may influence the immune response. Disruption of the biological clock may also impair the immune system’s ability to clear an infection.
With insomnia becoming increasingly common, the researchers highlighted the need to better understand the short- and long-term effects of disturbed sleep on infection-related outcomes.
The findings suggest that sleep may be a potentially modifiable factor in reducing the risk of long COVID and other post-infectious conditions.
“Promoting healthy sleep habits and minimizing circadian disruption could represent simple, low-cost strategies to reduce the long-term consequences of viral infections, particularly among people who work night shifts,” Kogevinas said.
Long COVID is a debilitating condition that can persist for months or even years after a SARS-CoV-2 infection. Long COVID is an infection-associated chronic condition marked by fatigue, cognitive impairment, exercise intolerance, and multisystem dysfunction.
It has affected an estimated 400 million people worldwide and continues to have significant health, social, and economic consequences. Despite the ongoing risk, prevention strategies have received relatively little attention.
© 2024 Bennett, Coleman & Company Limited